2012 Namn Projekttitel Summa 2012, okt Klara Hasselrot, Karolinska Institutet Hormonella preventivmedels effekt på

Transkript

1 , Andrea Introini, Karolinska Role of the immunoregulatory effect of semen in HIV- 1 transmission to the female genital mucosa Kajsa Noyan, Karolinska Viral suppression assay for HIV- specific CD8+ Treg s activity Dominic Papquin Prolux, Innate detection and elimination of HIV- 1 Karolinska , okt Annika Karlsson, Karolinska Impact of T cell functionality and pathogenesis on HIV reservoir size in subjects on long- term ART Edwin Leeansyah, Karolinska Exploring the antimicrobial and cytotoxic function of MAIT cells in HIV- 1 infection Britta Wahren & Eric Sandström, Extraordinär satsning: Optimering av HIVIS DNA vaccin 2 Karolinska 2013, Robin Löving, Karolinska How two broadly neutralizing anti HIV- 1 antibodies, PG9 and PG16, inactivate the virus Christopher Sundling, Karolinska Antibody maturation and diversity elicited by an HIV- 1 vaccine candidate Benjamin King, Lunds Universitet Inhibition of PKR by non- coding RNA nc886 and effect on HIV replication Arvid Edén, Sahlgrenska Akademin Longitudinell analys av neurologisk skada och viral escape i centrala nervsystemet vid HIVinfektion Bo Heideman, Venhälsan, Detektion av mukosalt IgA och IgG- svar hos HIV- Södersjukhuset immuniserade individer Anna Petrova, Karolinska Correlation of local immune activation with genital viral shedding in HIV infected women Rada Ellegård, Linköpings Universitet Initial events of HIV- 1 pathogenesis at the cervical and colorectal mucosa Jenny Svärd, Karolinska Correlation of serum flagellin with immune activation status in HIV patients Amanda Häggblom, Karolinska Långtidsuppföljning av HIV behandling I den svenska HIV kohorten , okt Klara Hasselrot, Karolinska Hormonella preventivmedels effekt på genitalslemhinna med avseende på motståndskraft mot HIV Rose Bosire, Karolinska Effect of antiretroviral prophylaxis on maternal antibody levels and transfer. Jenny Stenkvist, Karolinska Co- infektion med kronisk hepatit C hos HIV- infekterade patienter i Sverige 2012, Robin Löving, Karolinska How to broadly neutralizing anti HIV- 1 antibodies, PG9 and PG16, inactivate the virus Annelie Tjernlund, Karolinska Detailed in situ analysis of SIV- specific CD8T cells in lymphoid tissue Johan Winquist, Uppsala Universitet Identifying novel drug resistant inhibitor scaffolds of HIV protease by SPR aided fragment screening Jan Vesterbacka, Karolinska Effect of HIV therapy on gut microbiota

2 Amanda Häggblom, Karolinska Långtidsuppföljning av HIV behandling I den svenska HIV kohorten , okt Markus Moll HIV- 1 Vpu An inhibitor of innate immunity and a potential target for novel anti- retroviral drugs Johanna Brännström Sent diagnostiserad HIV- 1 infektion ett centralt problem i eran av HAART Klara Hasselrot Proteinuttryck i saliv och rektalsköljvätska hos HIV- exponerade icke infekterade MSM Tove Kaldensjö Assessment of mucosal factors of importance for HIV susceptibility in the female genital tract Christina Carlander Impact of HIV- induced immunosuppression and anti- retroviral therapy on the development of cervical n 2011, Harold Marcotte, Karolinska Lactobacillus mediated delivery of antibody kr fragments against HIV Ujjwal Neogi, Karolinska Human APOBEC mediated hypermutations induced kr drug resistance Pauline Levinson, Karolinska Immunological mechanisms of resistance to HIV kr acquisition in serodiscordant couples Mattias Mild, Karolinska Undersökning av den geografiska spridningen av HIV i kr Sverige och Östersjöområdet Marcus Buggert, Karolinska The early effects of antiviral treatment on CD4+ T cell kr reconstitution and immune activation Marianne Jansson, Karolinska On the role of microrna in HIV- Mtb coinfections kr Åsa Mellgren, Göteborgs Universitet Sahlgrenska Akademin Studie av HIV- associerade neurokognitiva symptom kr , okt Annelie Tjernlund, Karolinska Detailed in situ analysis of SIV- specific CD8 T cells in lymphoid tissue Markus Moll, Karolinska HIV interference with lipid- specific immunity An evolutionarily conserved immune evasion strategy? Karin Loré, Karolinska Defects in human dendritic cell subsets during HIV- 1 infection Jan Vesterbacka, Karolinska Effekt av HIV behandling på mikrobiell translokation Jarl Wikberg, Uppsala Universitet Development of proteochemometric based technologies for improvement of antiretroviral therapy in HIV 2010, Eva Agneskog Cross- resistance between etravirine and the first generation of NNRTI s by a simple phenotypic assay Jenny Nilsson Co- infektion med hepatit B och hepatit C hos HIV- infekterade patienter i Sverige Samir Abdurahman Immune Activation in HIV patients: The Role of Microbial Translocation & HMGB1 Annika Karlsson Identification of global anti- HIV- specific T cell responses Johan Sandberg NK cell responses and KIR- HLA interactions in the Ugandan HIV- 1 epidemic Amanda Häggblom Läkemedels resistens och behandlingsresultat av HIV typ 1

3 Linda Fogelstrand Naturliga antikroppar vid HIV- koppling till ökad aterosklerosutveckling? , nov Anders Sönneborg, Karolinska Effekt av influensa A(H1N1)v vaccination av HIV- infekterade Bo Hejdeman, Instutitionen Immunitet mot nya influensan (H1N1) efter vaccination Södersjukhuset hos människor med HIV- 1 infektion Piotr Nowak, Karolinska The central role of HMGB1 and bacterial products in kr immune modulation of HIV- 1 infection Marie Borggren, Lunds Universitet Studies on HIV- 1 Env glycan evolution and its affect on kr virus sensitivity to inhibitors Irene Bontell, Karolinska Resistensutveckling hos HIV- patienter i Stockholm kr Anna Smed- Sörensen, Karolinska THE ROLE OF DENDRITIC CELLS IN HIV kr TRANSMISSION: implications for HIV- 1 pathogenesis and therapy Klara Hasselrot, Karolinska Detektion av funktionella IgA- svar hos HIV- vaccinerade kr individer Aylin Yilmaz, Göteborgs Universitet Maraviroc koncentrationer i likvor hos HIV kr infekterade individer Mattias Mild, Karolinska Detailed Characterization of the Development of HIV kr Drug Resistance Sarah Palmer, Effects of treatment intensification with raltegravir on kr 2009, Eva Agneskog, Karolinska Johanna Brännström, Karolinska viral production in plasma and CSF Korsresistens mot etravirin bestämd med enkel fenotypisk metod Sent diagnostiserad HIV- 1 infektion, ett centralt problem i eran av HAART , nov Sarah Palmer, Raltegravir substitution for enfuvirtide in patients suffering from injection- site reactions Annika Karlsson, Identification of global anti- HIV- specific CTL Responses Markus Moll, Karolinska HIV- 1 interference with lipid- restricted immunity A novel link between HIV- 1 and AIDS- related Karolin Falconer, Karolinska 2008, juni Susanne Johansson, Aylin Yilmaz, Sahlgrenska Unversitetssjukhuset opportunistic infections Antiviral immune responses, HCV kinetics and assessment of interferon- induced depression in HCV/HIV- 1 coinfection Induction of NK- cell activity against HIV infected cells by antibody treatments Behandlingseffekt i likvor för antiretrovirala läkemedelskombinationer med olika bra CNS- penetrerande förmåga. Elin Andersson, Göteborgs Universitet Microbicides against HIV- 1 and HSV- 2 Jakob Michaelsson, Karolinska The Role of NK cells in HIV infection Klara Hasselrot, Karolinska Mucosal immunity in HIV- exposed uninfected men who have sex with men/partnerstudien Mattias Forsell, Production and Characterization of recombinant HIV- 1 envelope glycoproteins. 2008, Johan Lennerstrand, Uppsala Improved management of HIV by studies of novel

4 Universitet mechanisms of resistance to nucleoside analogs. Jarl Wikberg, Uppsala Universitet Development of proteochemometric models for drug resistance predicition in HIV. Taha Hirbod, Karolinska Function and regulation of the HIV- 1 specific mucosal immune response in genital tissue , Signar Mäkitalo, Akademiska Clinical outcome in patients with low CD4+ T- cell nov sjukhuset Uppsala counts despite effective HAART Mattias Mild, Ultra- deep sequence analysis of HIV R5 and X4 subpopulations 2007, juni Steven Appelquist, Karolinska Global Health Emergencies: Improving DNA- bases Vaccine Strategies to HIV Katarina Gyllensten, Karolinska Föreligger ökad frakturincidens i samband med ART? Gary Corrigan, Antiretroviral resistance mutations in the HIV- 1 genome result in reduction in reserve transcriptase fitness Styrgruppen för InfCareHIV, InfCareHIV kr Karolinska 2007, Piotr Nowak, Karolinska Immune activation in HIV- 1 infection The central role of HMGB1 complexes Helena Skar, Evolutionary imprint of clinical disease progression in HIV- 1 phylogenies Charlotte Hedskog, Ultra- deep sequencing to monitor previously- undetectible drug- resistance within HIV- 1 quasispecies Taha Hirbod, Karolinska Function and regulation of the HIV- 1 specific mucosal immune response in genital tissue , nov Ann Atlas, Karolinska Immunsystemetsreglering av kynurensyra samt dess betydelse för patofysiologin vid psykos hos HIV- 1 infekterade individer Markus Moll, Karolinska The CD1 system New target for HIV- 1 immune evasion Aylin Yilmaz, Sahlgrenska Intrathecal immune markers in HIV- 1- infected patients kr Unversitetssjukhuset on various antiretroviral treatment combinations Annika Karlsson, Identification of global anti- HIV- specific CTL responses Magnus Gisslén, Sahlgrenska NorthHIV- studien 2006, juni Gary Corrigan, Ann- Sofie Åsander, Karolinska Afrikanska föräldrar som lever med HIV- infektion i Sverige Marianne Jansson, Lunds universitet Studies on early and late HIV- 1 variants in relation to innate immunity selection forces Elin Andersson, Göteborgs Universitet Effects on HIV replication in vitro by a novel monosulphated cyclitolas a part of the project Microbicide prophylaxis against transmission of HIV and genital herpes in Tanzania. Piotr Nowak, Karolinska The role of HMGB- 1 in HIV infection Klara Hasselrot, Karolinska Mucosal immunity in HIV- exposed uninfected men who have sex with men/partnerstudien Lennart Svensson, Linköpings Kan Lewis a blockera DC- SIGN medierad spridning av

5 2006, Universitet sexuellt överför HIV? Magnus Gisslén, Sahlgrenska Immunologisk och virologisk effekt av IVIG som tillägg till antiretroviral terapi mot HIV Lars- Magnus Andersson, Sahlgrenska HIV- 1 co- receptortropism i CSF och blod longitudinell kr studie. Tobias Bergroth, Karolinska Resistensutveckling i mindre viruspopulationer mot lamivudin vid insättning av hiv- behandling samt i Annika Lindkvist, Karolinska parade blod/csf prover. Analysis of virological parameters in HIV- 1 Seropositive, but virus DNA/RNA- negative subjects , Eric Sandström, Södersjukhuset HIVIS 02. Säkerhet och immunogenicitet av att november immunisera med MVA med infogade HIV- 1 gener för env, gag, och pol I individer som tidigare fått motsvarande HIV- 1 gener i plasmid Magnus Gisslén, Sahlgrenska NORTHiv- studien Markus Moll, Karolinska Mechanisms of HIV- 1 interference with CD1d- restricted T cell- mediated immunity. Ali Harandi, Göteborgs Universitet Development of novel CpG DNA- based approaches for inhibition of HIV- 1 replication in vitro. 2005, juni Gunilla Karlsson Hedenstam, HIV- 1 envelope glycoprotein pseudotyping for Karolinska funcional and neutralization studies Marie Larsson, Hälsouniversitet Immunomodulatory effects of HIV- 1 on human Linköpig dendritic cells and subesquent T cell activation. Veronica Svedhem, Karolinska Expanded evolutionary analyses on the Swedish kr transmission chain Irina Maljkovic, Kinetics of mutation M184V in minor HIV- population with treatment failure on lamivudin, abacavir and didanosin. Del av projekt. Resistensutveckling vid läkemedelsbehandling. Eleonor Brandin, Evolution of HIV kr 2005, Björn Södergård, Readiness assessments in clinical practice. Predicting treatment outcome in HIV patients by the use of readiness assessments. NORTHiv- studien kr Magnus Gisslén, Sahlgrenska Eric Sandström, Södersjukhuset HIVIS 01 Johan Söderlund, Karolinska kr Immunologiska och genetiska faktorer associerade till skydd mot HIV- 1 infektion hos HIV- 1 exponerade seronegativa män som har sex med HIV- infekterade män , nov Ann Atlas, Karolinska Korrelation av IL- 7 och IL- 7R med CD4+T cells ökningen under behandling med ART. Babilonia Barqasho, Karolinska Betydelsen av innate immunitet vid primär hiv infektion och vid utsättning av behandling. Tobias Bergroth, Karolinska Resistensutveckling mot lamivudin vid insättning och utsättning av hiv- behandling. Victor Fernandez, Pneumocyctis jiroveci pneumonia: genetic monitoring kr

6 Ali Harandi, Göteborgs Universitet Gunilla Karlsson, Annelie Tjernlund, Karolinska 2004, juni Johan Lennerstrand, Karolinska Johan Sandberg, Karolinska 2004, Veronica Svedhem, Karolinska Göran Bratt, Södersjukhuset and rational drug selection. Development of novel CpG DNA- based approaches for inhibition of HIV- 1 replication in vitro. Stimulation of potent antibody and T helper responses against HIV- 1 using an optimized trimeric envelope immunogen. Leukemia inhibitory factor (LIF) en potent endogen kr hämmare av HIV- 1. Improvement of treatment of HIV by studies of mechanism of resistance to NRTI s. Hepatit C virus dynamics and anti- viral immune responses in HCV/HIV- 1 co- infected patients treated with PEG interferon alfa- 2a and Ribavirin. Resistensutveckling vid behandlingssvikt. 7- årsuppföljning av de 202 patienter som startade antiretroviral kombinationsbehandling (HAART) vid Venhälsan under , nov Nathalie Ylitalo, Karolinska Long- term evaluation of adverse effects among kr uninfected children born to HIV- infected women and exposed to antiretroviral therapy perinatally. Angelo De Milito, Karolinska Impact of early HAART on memory B cells and specific anti- HIV humoral immunity during primary HIV infection. 2003, juni Andreas Boberg, Utveckling av vaccine mot drogresistent HIV kr Sven Britton, Lågkostnadsalternativ för bestämning och kontroll av HIV infektion. Anna- Lena Spetz, Karolinska From mice to man with the novel therapeutic HIV- 1 vaccine strategy; apoptotic HIV- 1 infected cells. Annelie Tjernlund, Karolinska Leukemia inhibitory factor (LIF) en potent endogen hämmare av HIV kr 2003, Tobias Bergroth, Karolinska Resistensutveckling mot lamivudin vid insättning och utsättning av HIV behandling. Ali Harandi, Göteborgs Universitet Immunostimulatory CpG DNA- based strategies for inducing protective immunity in the female genital tract mucosa against HIV and HSV- 2. Anna Lindström, Karolinska Reversion av resistensmutationer efter smitta med resistent virus. Yu Shi, Karolinska Autologous HIV- 2 neutralisation in relation to clinical progression , nov Homira Behbahani, Karolinska Horizontal gene transfer by the uptake of apoptotic kr HIV- 1 infected cells A novel vaccine strategy. Angelo De Milito, Karolinska Impact of early HAART on memory B cells and specific kr anti- HIV humoral immunity during primary HIV infection. Johan Lennerstrand, Karolinska Improvement of treatment of HIV by studies of mechanisms of resistance to NRTI s Lilian Walther- Jallow, Karolinska Ett terapeutiskt HIV vaccin baserat på horisontell kr

7 gentransfer metod. 2002, juni Babilonia Barqasho, Karolinska Betydelsen av innate immunitet för immunförsvaret vid primär HIV infektion och vid utsättning av behandling. Nico Dantuma, Karolinska Development of a diagnostic phenotypic assay for the kr identification of protease inhibitor resistant HIV- 1 strains in AIDS patients. Lars Eriksson, Utveckling av HIV- 1 DNA nivåer vid behandlings kr uppehåll. Veronica Svedhem, Karolinska Kliniska aspekter på HIV- 1 resistens vid behandling med nelfinavir. 2002, Tobias Bergroth, Karolinska Fitness of HIV- 1 strains resistant to nucleoside reverse transcriptase inhibitors. Eleonor Brandin, Karolinska Antiretroviral resistance in Swedish HIV- 2 patients. Anna Lindström, Karolinska AZT resistance in pregnant women receiving kr prophylaxis against mother- to- child transmssion of HIV- 1 Linda Morfeldt, Karolinska HiVBivus En prospektiv kohortstudie kring kr biverkningar av antiretroviral terapi. Piotr Nowak, Karolinska The role of HMGB- 1 in HIV infection.